A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Pirtobrutinib (Primary) ; Acalabrutinib; Ibrutinib; Zanubrutinib
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms BRUIN MCL-321
- Sponsors Loxo Oncology
- 10 May 2024 Planned End Date changed from 1 Apr 2025 to 1 Jul 2026.
- 10 May 2024 Planned primary completion date changed from 1 Apr 2025 to 1 Dec 2025.
- 10 May 2024 Status changed from recruiting to active, no longer recruiting.